The Administrative Core (Core A) will provide overall scientific leadership and governance for the CFAR. It will provide overall administration and coordination of all CFAR Cores, SWGs and activities, and will orchestrate communication among CFAR stakeholders (including CFAR faculty, community members, external and internal advisory boards, NIAID program staff, and UR institutional leadership). During our funding cycle as a Developmental CFAR (D-CFAR), this Core has developed an innovative approach to building multidisciplinary research collaborations (scientific """"""""speed dating""""""""). It has also conducted strategic planning that has addressed investigator needs, improved core services, created a new institutional partnership to enhance drug discovery research, and identified research opportunities that have resulted in new funding for young faculty. The Core will be responsible for: (1) setting policies and procedures for the CFAR;(2) providing transparent financial management and ensuring regulatory compliance;(3) overseeing all CFAR Cores, SWGs and activities;determining scientific priorities and resource allocation (including pilot awards);(4) organizing and coordinating key CFAR committees and advisory boards, as well as the annual CFAR retreat and NIH site visit;(5) maintaining open lines of communication between CFAR members, other stakeholders, and CFAR leadership;(6) ensuring that the CFAR is highly visible on campus, and has a voice in UR research policy and recruitment;(7) conducting regular, inclusive, strategic planning sessions that inform CFAR decision-making;(8) promoting internal and external research partnerships that result in new multidisciplinary collaborations;(9) ensuring that the CFAR effectively leverages unique research strengths at UR, thereby creating a distinctive scientific identity for itself;and (10) conducting innovative, rigorous programmatic evaluation that results in effective decision-making - leading to improved services and enhanced outcomes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI078498-07
Application #
8712924
Study Section
Special Emphasis Panel (ZAI1-UKS-A)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
7
Fiscal Year
2014
Total Cost
$342,772
Indirect Cost
$119,468
Name
Case Western Reserve University
Department
Type
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Ocque, Andrew J; Hagler, Colleen E; Morse, Gene D et al. (2018) Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid. J Pharm Biomed Anal 156:163-169
McMillan, JoEllyn; Szlachetka, Adam; Slack, Lara et al. (2018) Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrob Agents Chemother 62:
Piekna-Przybylska, Dorota; Nagumotu, Kavyasri; Reid, Danielle M et al. (2018) HIV-1 infection renders brain vascular pericytes susceptible to the extracellular glutamate. J Neurovirol :
Braksmajer, Amy; Simmons, Janie; Aidala, Angela et al. (2018) Effects of Discrimination on HIV-Related Symptoms in Heterosexual Men of Color. Am J Mens Health 12:1855-1863
Loelius, Shannon G; Lannan, Katie L; Blumberg, Neil et al. (2018) The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro. Thromb Res 169:96-104
Loelius, Shannon G; Spinelli, Sherry L; Lannan, Katie L et al. (2018) In Vitro Methods to Characterize the Effects of Tobacco and Nontobacco Products on Human Platelet Function. Curr Protoc Toxicol 76:e46
Rice, John D; Strawderman, Robert L; Johnson, Brent A (2018) Regularity of a renewal process estimated from binary data. Biometrics 74:566-574
Nogales, Aitor; Piepenbrink, Michael S; Wang, Jiong et al. (2018) A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody. Sci Rep 8:4374
Zhou, Tian; Su, Hang; Dash, Prasanta et al. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151:53-65
Horita, Yasuhiro; Alsultan, Abdullah; Kwara, Awewura et al. (2018) Evaluation of the Adequacy of WHO Revised Dosages of the First-Line Antituberculosis Drugs in Children with Tuberculosis Using Population Pharmacokinetic Modeling and Simulations. Antimicrob Agents Chemother 62:

Showing the most recent 10 out of 192 publications